SBC
SBC Medical Group Holdings Incorporated
Consulting Services
Market Cap$329M
5Y Perf.-68.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SBC vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-77.8%
SBC vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SBC | NVCR |
|---|---|---|
| Industry | Consulting Services | Medical - Instruments & Supplies |
| Market Cap | $329M | $1.92B |
| Revenue (TTM) | $178M | $674M |
| Net Income (TTM) | $43M | $-173M |
| Gross Margin | 73.7% | 75.2% |
| Operating Margin | 33.3% | -27.2% |
| Forward P/E | 7.1x | — |
| Total Debt | $12M | $290M |
| Cash & Equiv. | $125M | $103M |
SBC vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SBC
NVCR
| Stock | Sep 22 | May 26 | Return |
|---|---|---|---|
| SBC Medical Group H… (SBC) | 100 | 32.0 | -68.0% |
| NovoCure Limited (NVCR) | 100 | 22.2 | -77.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SBC vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SBC leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NovoCure Limited is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
SBC
SBC Medical Group Holdings Incorporated
The Income Pick
SBC carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.76
- Lower volatility, beta 0.76, Low D/E 6.3%, current ratio 3.01x
- Beta 0.76, current ratio 3.01x
Best for: income & stability and sleep-well-at-night
NVCR
NovoCure Limited
The Growth Play
NVCR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 30.3% 10Y total return vs SBC's -67.8%
- 8.3% revenue growth vs SBC's 6.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs SBC's 6.1% |
| Quality / Margins | SBC | 24.3% margin vs NVCR's -25.7% |
| Stability / Safety | SBC | Beta 0.76 vs NVCR's 2.20, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVCR | +1.1% vs SBC's +0.3% |
| Efficiency (ROA) | SBC | 13.5% ROA vs NVCR's -16.5%, ROIC 72.3% vs -16.4% |
SBC vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSBCLAGGINGNVCR
NVCRNovoCure Limited
0leads
SBCSBC Medical Group Hol…
2leads
6 Total Categories
CATEGORYLEADERvs NVCRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
SBC2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SBC9/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — SBC and NVCR each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 3.8x SBC's $178M. SBC is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SBCSBC Medical Group… | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $178M | $674M |
| EBITDAEarnings before interest/tax | $62M | -$165M |
| Net IncomeAfter-tax profit | $43M | -$173M |
| Free Cash FlowCash after capex | -$37M | -$48M |
| Gross MarginGross profit ÷ Revenue | +73.7% | +75.2% |
| Operating MarginEBIT ÷ Revenue | +33.3% | -27.2% |
| Net MarginNet income ÷ Revenue | +24.3% | -25.7% |
| FCF MarginFCF ÷ Revenue | -20.5% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -18.3% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +3.2% | -100.0% |
Evenly matched — SBC and NVCR each lead in 3 of 6 comparable metrics.
Valuation Metrics
SBC leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SBCSBC Medical Group… | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $329M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $216M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | 6.65x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.07x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 2.92x | — |
| Price / SalesMarket cap ÷ Revenue | 1.60x | 2.92x |
| Price / BookPrice ÷ Book value/share | 1.59x | 5.51x |
| Price / FCFMarket cap ÷ FCF | 19.17x | — |
SBC leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
SBC leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
SBC delivers a 17.5% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. SBC carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), SBC scores 7/9 vs NVCR's 5/9, reflecting strong financial health.
| Metric | SBCSBC Medical Group… | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | +17.5% | -50.8% |
| ROA (TTM)Return on assets | +13.5% | -16.5% |
| ROICReturn on invested capital | +72.3% | -16.4% |
| ROCEReturn on capital employed | +37.9% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.06x | 0.85x |
| Net DebtTotal debt minus cash | -$113M | $187M |
| Cash & Equiv.Liquid assets | $125M | $103M |
| Total DebtShort + long-term debt | $12M | $290M |
| Interest CoverageEBIT ÷ Interest expense | 596.05x | -96.80x |
SBC leads this category, winning 9 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — SBC and NVCR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SBC five years ago would be worth $3,223 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, NVCR leads with a +1.1% total return vs SBC's +0.3%. The 3-year compound annual growth rate (CAGR) favors SBC at -32.2% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | SBCSBC Medical Group… | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | -25.9% | +28.3% |
| 1-Year ReturnPast 12 months | +0.3% | +1.1% |
| 3-Year ReturnCumulative with dividends | -68.9% | -75.7% |
| 5-Year ReturnCumulative with dividends | -67.8% | -91.3% |
| 10-Year ReturnCumulative with dividends | -67.8% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -32.2% | -37.6% |
Evenly matched — SBC and NVCR each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — SBC and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
SBC is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs SBC's 55.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SBCSBC Medical Group… | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | 2.20x |
| 52-Week HighHighest price in past year | $5.75 | $20.06 |
| 52-Week LowLowest price in past year | $2.97 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +55.8% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 29.9 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 87K | 1.5M |
Evenly matched — SBC and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates SBC as "Buy" and NVCR as "Buy". Consensus price targets imply 180.4% upside for SBC (target: $9) vs 99.0% for NVCR (target: $34).
| Metric | SBCSBC Medical Group… | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $33.50 |
| # AnalystsCovering analysts | 1 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SBC leads in 2 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 3 categories are tied.
Best OverallSBC Medical Group Holdings … (SBC)Leads 2 of 6 categories
Loading custom metrics...
SBC vs NVCR: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is SBC or NVCR a better buy right now?
For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.
3% revenue growth year-over-year, versus 6. 1% for SBC Medical Group Holdings Incorporated (SBC). SBC Medical Group Holdings Incorporated (SBC) offers the better valuation at 6. 7x trailing P/E (7. 1x forward), making it the more compelling value choice. Analysts rate SBC Medical Group Holdings Incorporated (SBC) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SBC or NVCR?
Over the past 5 years, SBC Medical Group Holdings Incorporated (SBC) delivered a total return of -67.
8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus SBC's -67. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SBC or NVCR?
By beta (market sensitivity over 5 years), SBC Medical Group Holdings Incorporated (SBC) is the lower-risk stock at 0.
76β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 190% more volatile than SBC relative to the S&P 500. On balance sheet safety, SBC Medical Group Holdings Incorporated (SBC) carries a lower debt/equity ratio of 6% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — SBC or NVCR?
By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.
3% versus 6. 1% for SBC Medical Group Holdings Incorporated (SBC). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to 15. 5% for SBC Medical Group Holdings Incorporated. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — SBC or NVCR?
SBC Medical Group Holdings Incorporated (SBC) is the more profitable company, earning 22.
7% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBC leads at 34. 2% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — SBC leads at 76. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is SBC or NVCR more undervalued right now?
Analyst consensus price targets imply the most upside for SBC: 180.
4% to $9. 00.
07Which pays a better dividend — SBC or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is SBC or NVCR better for a retirement portfolio?
For long-horizon retirement investors, SBC Medical Group Holdings Incorporated (SBC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
76)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SBC: -67. 8%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SBC and NVCR?
These companies operate in different sectors (SBC (Industrials) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SBC is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(SBC: -18.3% · NVCR: 12.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.